New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2012
06:14 EDTXOM, MHS, PEUGY, ESRX, GMOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: GM (GM) and PSA Peugeot Citroen (PEUGY) look to begin joint development of at least two passenger cars by this fall, says GM CEO Akerson, the Wall Street Journal reports...Venture capital for biotechnology has been in decline, due to the economy and poor returns from stock offerings. VC's invested $3.92B in 2011 vs. $6.17B in 2007, according to VentureSource, the Wall Street Journal reports...REUTERS: Exxon Mobil (XOM) informed the Iraqi government that it froze its exploration deal with the semi-autonomous Kurdistan region which angered Baghdad which it considers illegal, Reuters reports...BLOOMBERG: Not since 1999 have currency traders been bullish on the dollar for so long, a sign that the market sees the U.S. resuming its role as the engine of global economic growth, Bloomberg reports...Express Scripts' (ESRX) bid to acquire Medco Health Solutions (MHS) and create the largest U.S. pharmacy-benefits manager may be delayed by a lawsuit being considered by five states, Bloomberg reports.
News For GM;PEUGY;XOM;ESRX;MHS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
November 23, 2015
06:24 EDTGMGM uses KBB to offer targeted incentives, Automotive News reports
General Motors has turned to Kelley Blue Book's website to offer targeted incentives to customers, Automotive News reports. Reference Link
05:46 EDTXOMStocks with implied volatility movement; X XOM
Subscribe for More Information
November 22, 2015
18:46 EDTGMUAW union ratifies General Motors agreement
The United Auto Workers announced that its international executive board has formally ratified the national labor agreement with General Motors. The union explained that, after its proposed agreement with GM was blocked by the union's skilled trades members, it held meetings with those members and subsequently presented their concerns to both union leadership and GM itself. Following those discussions, the parties agreed to changes that "protect core trades classifications and seniority rights," according to UAW. Reference Link
13:11 EDTESRXExpress Scripts' link to specialty drug makers presents new risk, Barron's says
Express Scripts' (ESRX) United BioSource unit -- often hired by specialty drug makers to help patients find money for costly treatments -- appears at odds with the company's role in negotiating lower drug prices, Barron's contends in a feature article. Though Express Scripts will continue to earn the "vast majority" of its profits as a pharmacy-benefit manager, Barron's argues that investors should view its work on behalf of specialty drug companies as a risk factor for the stock, particularly in light of recent Valeant (VRX) and Horizon (HZNP) headlines. Reference Link
November 20, 2015
18:58 EDTESRXExpress Scripts management to meet with JPMorgan
Meeting to be held in New York on November 24 hosted by JPMorgan.
November 19, 2015
07:55 EDTGMGM's Reuss: Company 'deeply committed' to EVs, FT says
Subscribe for More Information
November 18, 2015
16:45 EDTXOMOn The Fly: Top stock stories for Wednesday
Stocks on Wall Street were higher from the opening bell onward despite housing starts data that was weaker than expected. Investors waited for the release of the FOMC minutes and saw what they had suspected; that the Fed was reinforcing its message that the December meeting is an option for the central bank to begin raising interest rates. The visibility on rates gave investors confidence, leading to a late-day rally that saw the averages close at their highs. ECONOMIC EVENTS: In the U.S., the minutes from the Fed's last FOMC meeting showed that most participants expect that rate hike conditions will be met by their December meeting. The Fed repeated its constant refrain, though, that the actual decision would depend on the implications for the medium-term outlook from recent economic data. Housing starts fell 11.0% to a 1.06M pace in October, weaker than the expected rate of 1.16M. Building permits, however, rose 4.1% to a 1.15M rate, versus an expected rise of 3.8%. COMPANY NEWS: Shares of Target (TGT) fell 4.3% to $69.78 after the retailer reported in-line quarterly sales and profits and narrowed the range of its fiscal year earnings view. Target, which guided for same-store sales in the new quarter to be up 1%-2%, added that it sees "indications of heavy inventory levels" at some competitors into the holiday season... Shares of Apple (AAPL) climbed 3.17% to $117.29 after Goldman Sachs added the stock to its Conviction Buy List, predicting that investors should begin to focus on the company's monetization and recurring revenue opportunities over the next year, which would be a boon to its valuation... Raymond James analyst Pavel Molchanov downgraded Exxon Mobil to Underperform, the firm's equivalent to a "Sell" rating, saying he expects a modest oil recovery in 2016 but that Exxon's limited leverage to oil prices will act as a hindrance during a recovery. Despite Molchanov predicting Exxon shares to be a source of funds for investors turning more constructive on oil in 2016, the stock rose about 1% to $80.74 today amid a rally in oil prices. MAJOR MOVERS: Among the notable gainers was Fairchild (FCS), which jumped $1.52, or 8.5%, to $19.40 after agreeing to be acquired for $20 per share by ON Semiconductor (ON), whose stock fell 7.9% to $9.89 after the news. Also higher were Canadian Pacific (CP) and Norfolk Southern (NSC), with the two railway operators advancing a respective 5.8% and 6.35% after Canadian submitted a bid to acquire Norfolk, though the latter immediately criticized the offer as "low-premium." Additionally, ConAgra (CAG) gained 4% to $40.93 after announcing plans to separate into two independent public companies. Among the noteworthy losers was Qualcomm (QCOM), which dropped $4.98, or 9.4%, to $48.00 after disclosing that Korea's Fair Trade Commission alleged the company does not "properly negotiate" aspects of its licenses and may be violating Korean competition law. Also lower was Sprint (S), which fell 9.3%, to $3.99 after announcing a 50% discount for new customers switching from competing wireless carriers. GoPro (GPRO) declined 5.1% to $19.81 after research firm Piper Jaffray noted that the company has been offering discounts on its cameras, including featuring them on "flash sale" sites, and cut its price target on the stock to $15 per share. INDEXES: The Dow rose 247.66, or 1.42%, to 17,737.16, the Nasdaq gained 89.19, or 1.79%, to 5,075.20, and the S&P 500 advanced 33.14, or 1.62%, to 2,083.58.
15:40 EDTESRXCongressman says U.S. may need look at pharmacy competition, dealReporter says
Subscribe for More Information
10:02 EDTXOMOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Citrix (CTXS) downgraded to Neutral from Buy at Mizuho... Diana Shipping (DSX) downgraded to Hold from Buy at Deutsche Bank... Exxon Mobil (XOM) downgraded to Underperform from Market Perform at Raymond James... Hartford Financial (HIG) downgraded to Hold from Buy at Argus... Kinder Morgan (KMI) downgraded to Buy from Conviction Buy at Goldman... Kinross Gold (KGC) downgraded to Market Perform from Outperform at Raymond James... Nuverra Environmental (NES) downgraded to Market Perform from Outperform at Cowen... Oxford Lane (OXLC) downgraded to Hold from Buy at Maxim... SM Energy (SM) downgraded at BMO Capital... Scorpio Bulkers (SALT) downgraded to Hold from Buy at Deutsche Bank... Star Bulk Carriers (SBLK) downgraded to Hold from Buy at Deutsche Bank... StoneCastle (BANX) downgraded to Market Perform from Outperform at Keefe Bruyette... Suncor (SU) downgraded to Hold from Buy at TD Securities... ZS Pharma (ZSPH) downgraded to Neutral from Buy at Citi.
09:32 EDTGMThe House Oversight & Government Reform Committee to hold a hearing
Subscribe for More Information
07:57 EDTGMBarclays to hold a conference
Subscribe for More Information
07:43 EDTXOMExxon Mobil downgraded to Underperform on subpar oil leverage at Raymond James
As previously reported, Raymond James downgraded Exxon Mobil to Underperform from Market Perform. Analyst Pavel Molchanov expects a modest oil recovery in 2016 and said Exxon Mobil's limited leverage to oil prices will act as a hindrance during a recovery. Molchanov expects Exxon shares to be a source of funds for investors turning more constructive on oil in 2016. The analyst said this is not a short-term trading call but a 6-12 month time horizon, which could prove wrong if oil spends the year below $50 territory.
06:36 EDTXOMExxon Mobil downgraded to Underperform from Market Perform at Raymond James
Subscribe for More Information
November 17, 2015
10:17 EDTESRXHouse Judiciary Committee to hold a hearing
The Subcommittee on Regulatory Reform, Commercial and Antitrust Law holds a hearing entitled, "The State of Competition in the Pharmacy Benefit Manager and Pharmacy Marketplaces" with Vice President Bricker of Express Scripts and Senior Vice President Pons of CVS Health on November 17 at 3 pm. Webcast Link
November 16, 2015
09:59 EDTGMOmega bought Valeant in Q3, sold some SuneEdison
Leon Cooperman's Omega Advisors gave a quarterly update on its stakes in a filing this morning, disclosing its positions as of September 30. NEW STAKES: Pfizer (PFE), Valeant (VRX) Walgreens Boots Alliance (WBA), TerraForm Global (GLBL), Cigna (CI). INCREASED STAKES: Google Class A (GOOGL), Facebook (FB), Delta Air Lines (DAL). DECREASED STAKES: SunEdison (SUNE), Shire (SHPG), Citi (C), KAR Auction (KAR), LyondellBasell (LYB). LIQUIDATED STAKES: McKesson (MCK), 21st Century Fox (FOXA), General Motors (GM), QEP Resources (QEP), eBay (EBAY).
09:06 EDTESRXDiplomat seen as compelling amid specialty pharmacy fallout
Shares of specialty pharmacy operator Diplomat Pharmacy (DPLO) and pharmacy benefit manager Express Scripts (ESRX) have each been knocked down by the negative news surrounding the sector amid the troubles faced by Valeant (VRX) and others, but an analyst at Leerink contends in a note to investors that the pullbacks in both stocks provide buying opportunities. BACKGROUND: Drugmaker Valeant and its prior specialty pharmacy partner, Philidor Rx Services, have been at the center of the firestorm engulfing the sector. Following claims that Philidor urged its employees to modify prescriptions to ensure more orders of Valeant-branded drugs rather than generics, as well as other allegations of wrongdoing, Express Scripts (ESRX) and peer CVS Health (CVS) terminated Philidor from their networks. The day after those termination announcements, Valeant said that it was severing all ties with Philidor and that the pharmacy planned to shut down operations as soon as possible, consistent with applicable laws. Valeant has subsequently said that Philidor has committed to cease operations by January 30, 2016, at the latest. More recently, Express Scripts, the nation's largest pharmacy benefit manager, announced that it stopped doing business with Linden Care, accusing it of being a "captive" pharmacy that dispenses mostly products made by Horizon Pharma (HZNP). In turn, Horizon called the idea that Linden Care is a captive pharmacy "entirely false," stating that "at best Express Scripts is being reckless in its allegations and at worse it is intentionally attempting to mislead investors." Express Scripts' move also impacted shares of Insys Therapeutics (INSY), which reportedly also used Linden Care to fulfill prescription for its drugs. DIPLOMAT LIKELY TO STAY IN-NETWORK: Leerink analyst David Larsen acknowledged that recent events indicate that Express Scripts appears to be evaluating certain retail pharmacies and their relationships with manufacturers, but he believes Diplomat's mix of drugs for diseases like multiple sclerosis, HIV, hepatitis C and cancer differentiate it as a "true" specialty pharmacy. Larsen does not think Diplomat is at risk of being excluded from the pharmacy networks of Express Scripts, CVS or UnitedHealth's (UNH) Optum, he tells investors. Larsen expects limited distribution agreements to stay an important channel strategy for drugmakers and believes these agreements are appropriate for high cost specialty drugs that require special handling and additional services to manage patient adherence. The analyst, who thinks Diplomat remains well positioned to deliver annual growth of over 30% in the next several years, keeps an Outperform rating on its shares. EXPRESS BUYING OPPORTUNITY: Larsen also thinks concerns around manufacturer and pharmacy relationships have put unwarranted pressure on shares of Express Scripts. He does not expect Express Scripts to disclose new lawsuits around rebate dollars owed over other manufacturer disputes and keeps an Outperform rating on the stock, which he views as having an "attractive" valuation. WHAT'S NOTABLE: Larsen also thinks that the specialty channel remains an opportunity for Walgreens Boots Alliance (WBA) and believes its proposed acquisition of Rite Aid (RAD) can strengthen its specialty offering. The analyst keeps an Outperform rating on Walgreens shares as well. PRICE ACTION: Over the last three months, Diplomat Pharmacy shares have declined 28%, Express Scripts has fallen 6% and Walgreens has dropped 14%.
07:36 EDTGMBerkshire Hathaway discloses new AT&T stake in quarterly update
Berkshire Hathaway gave a quarterly update on its stakes in a filing this morning. NEW STAKES: AT&T (T), Kraft Heinz (KHC), Liberty Lilac Group (LILA). INCREASED STAKES: Phillips 66 (PSX), Charter (CHTR), Liberty Media (LMCK), Suncor (SU), General Motors (GM). DECREASED STAKES: Goldman Sachs (GS), Wal-Mart (WMT), Deere (DE), Chicago Bridge & Iron (CBI), WABCO (WBC). LIQUIDATED STAKES: Viacom (VIAB).
06:51 EDTXOMBig energy firms saw 70% earnings dip for first nine months, WSJ says
Subscribe for More Information
06:18 EDTESRXDiplomat Pharmacy selloff brings 'compelling' entry point, says Leerink
Subscribe for More Information
06:08 EDTXOMExxon Mobil, Rosnet partnership is 'long-term,' Reuters reports
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use